A Randomized, Double-Blind, Patient-Self-Controlled Clinical Trial Evaluating the Efficacy and Safety of 2% Crisaborole Ointment Combined with 308-nm Excimer Laser for the Treatment of Non-Segmental Vitiligo

A Randomized, Self-Controlled, Left-Right Comparative Study on the Efficacy and Safety of Crisaborole Ointment Combined with 308-nm Excimer Laser in the Treatment of Non-Segmental Vitiligo

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600125285

Enrollment

Unknown

Registered

2026-05-25

Start date

2026-07-07

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Interventions

Intervention Group:The target lesion will receive topical crisaborole 2% ointment applied twice daily, combined with 308-nm excimer laser treatment twice weekly.

Control Group:The contralateral symmetrical target lesion will receive a topical vehicle/placebo ointment (identical in appearance and texture to the active ointment) applied twice daily, combined wit

Eligibility

Sex/Gender

All

Age

16 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Male or female patients aged 18 to 65 years. 2. Diagnosed with non-segmental vitiligo. 3. Disease in a stable phase (no new lesions or expansion of existing lesions in the past 6 months). 4. Presence of at least two comparable, symmetrical vitiligo lesions on the left and right sides of the body, suitable for comparison. 5. Willing and able to provide written informed consent and adhere to the study protocol.

Exclusion criteria

Exclusion criteria: 1. Segmental vitiligo. 2. Pregnant or lactating females. 3. Known hypersensitivity to crisaborole or any components of the ointment. 4. History of photosensitivity disorders or skin cancer. 5. Use of systemic immunosuppressants, systemic corticosteroids, or other vitiligo treatments within the past 3 months. 6. Use of topical vitiligo treatments on the target lesions within the past 4 weeks. 7. Participation in another clinical trial concurrently or within the past 30 days.

Design outcomes

Primary

Measure	Time frame
Vitiligo Area Scoring Index (VASI) ;Facial-VASI;	—

Secondary

Measure	Time frame
Mean percentage change in VASI/F-VASI score from baseline;Time to first appearance of visible repigmentation;Recurrence rate;Patient-reported satisfaction scores;	—

Countries

China

Contacts

Public ContactDanping Pan

The Fifth People's of Hainan Province

pandanping904@163.com+86 138 0757 9878

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026